Skip to main content
Premium Trial:

Request an Annual Quote

Editas Medicine: Jim Mullen

Jim Mullen has been appointed as CEO of Editas Medicine, where he will replace Cindy Collins. He will take up his new post Feb. 15 and will continue to serve as chairman of the company's board of directors, a role he assumed in March 2018. Previously, Mullen was CEO and a director of Patheon, a contract development and manufacturing organization that was acquired by Thermo Fisher Scientific in 2017. Prior to that, he was president and CEO of Biogen, where he previously held various other positions, including chief operating officer, VP international, and VP of operations. He is also a member of the board of the directors of Thermo Fisher Scientific. Mullen holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.